Loading...
Back to narrative

QLINEA: Expanded Sepsis Panel Approval Will Drive Strong Future Upside

Overvaluation Will Persist As Italy And US Markets Evolve

QLINEA logo
QLINEA
AnalystConsensusTarget
Not Invested
Published 13 Jul 2025

Update shared on 15 Dec 2025

Previous
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
-97.9%
7D
-10.5%

Narrative Update on Q-linea

The analyst price target for Q-linea was maintained at SEK 53.00, as analysts cite largely unchanged assumptions around long term revenue growth, profitability, and valuation multiples, with only immaterial model refinements to the discount rate and future earnings expectations.

What's in the News

  • Q-linea completed a SEK 312.4 million follow-on rights offering of ordinary shares, strengthening the balance sheet and funding growth initiatives (company filing).
  • The company submitted an FDA 510(k) application to expand organism and antimicrobial claims for the ASTar BC G panel, aiming to align the US panel with the IVDR cleared version used in the EU and broaden sepsis treatment options (company announcement).
  • The board appointed Stuart Gander as CEO, with former CEO Anders Ljunggren transitioning to deputy CEO, formalizing a leadership structure that reflects Gander's expanded operational role (board announcement).
  • CFO Christer Samuelsson will leave Q-linea after an orderly transition to a new CFO, expected during the first half of 2026, signaling an upcoming change in the finance leadership team (company announcement).
  • A prominent US level 1 university hospital trauma center became the first to convert from Accelerate Pheno to ASTar for routine clinical use, underscoring growing US adoption of Q-linea's rapid AST platform (client announcement).

Valuation Changes

  • Consensus Analyst Price Target: Unchanged at SEK 53.0, indicating no revision to the assessed fair value.
  • Discount Rate: Fallen slightly from 5.96 percent to 5.94 percent, reflecting a marginally lower assumed risk profile.
  • Revenue Growth: Essentially unchanged at around 208.34 percent, with only immaterial model refinements.
  • Net Profit Margin: Essentially unchanged at around 8.07 percent, indicating stable long term profitability assumptions.
  • Future P/E: Edged down slightly from 17.39x to 17.38x, signaling a minimal adjustment to valuation multiples.

Have other thoughts on Q-linea?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.